Stock Research: Xeris Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Xeris Pharmaceuticals

NasdaqGS:XERS US98422E1038
37
  • Value
    8
  • Growth
    99
  • Safety
    Safety
    33
  • Combined
    37
  • Sentiment
    44
  • 360° View
    360° View
    37
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing products across a range of therapies. It operates in the biopharmaceutical industry, with main businesses in commercially available products like Recorlev, Gvoke, and Keveyis, and a pipeline of development programs. The description does not specify regions of operation. In the last fiscal year, the company had a market cap of $844 million, profits of $166 million, revenue of $203 million, and 394 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Xeris Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Xeris Pharmaceuticals. The consolidated Growth Rank has a good rank of 99, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 99% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 33 means that the share price of Xeris Pharmaceuticals is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 67% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 8, which means that the company has a riskier financing structure than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 44, indicating professional investors are more pessimistic about the stock than for 56% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 63 21 75
Growth
99 79 65 59
Safety
Safety
8 11 18 11
Sentiment
44 68 56 22
360° View
360° View
37 55 25 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 100 92 85
Opinions Change
50 36 50 50
Pro Holdings
n/a 57 31 10
Market Pulse
47 47 27 22
Sentiment
44 68 56 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 63 21 75
Growth
99 79 65 59
Safety Safety
8 11 18 11
Combined
37 50 9 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
17 24 24 24
Price vs. Earnings (P/E)
34 43 67 56
Price vs. Book (P/B)
97 97 1 100
Dividend Yield
1 1 1 1
Value
33 63 21 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
78 78 76 97
Profit Growth
86 34 63 32
Capital Growth
100 81 10 70
Stock Returns
99 75 87 17
Growth
99 79 65 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
3 5 9 21
Refinancing
31 32 55 57
Liquidity
34 31 29 13
Safety Safety
8 11 18 11

Similar Stocks

Discover high‑ranked alternatives to Xeris Pharmaceuticals and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.